CELU (Celularity) Moat Score: 3/10 (As of Jul. 08, 2026)


CELU Celularity Inc CELU
31 GF Score
Price $0.75
GF Value $2.28
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Celularity Moat Score?

Celularity CELU -9.16% 31 Moat Score is 3 as of Jul. 08, 2026. GuruFocus rates CELU with a GF Score™ of 31/100 and a GF Value™ of $2.28 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,394 Biotechnology companies, Celularity ranks better than 75.54% on this metric.

Celularity has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Celularity has No Moat: Celularity Inc operates in a highly competitive biotech sector with limited market share and lacks significant intellectual property or regulatory advantages. Its innovation potential is promising but not yet proven to provide a durable moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Celularity might have No Moat - Very weak/transient advantages.

Celularity  (NAS:CELU) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Celularity Moat Score Related Terms

CELU vs GRTX, BCDA, KTTA: Moat Score Comparison

For the Biotechnology subindustry, Celularity's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celularity Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celularity's Moat Score distribution charts can be found below:

* The bar in red indicates where Celularity's Moat Score falls into.


CELU
31GF Score
Celularity Inc CELU
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Celularity (CELU) has a Moat Score of 3 as of Jul. 08, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Celularity ranks #341 out of 1394 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Celularity's Moat Score too high?
Celularity's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Celularity's value of 3 is 50% above this industry median. Based on the distribution chart, Celularity ranks #341 out of 1394 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Celularity has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Celularity's Moat Score compare to GRTX and BCDA?
According to the Biotechnology industry distribution chart, Celularity ranks #341 out of 1394 companies for Moat Score. This places Celularity in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Celularity's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,394 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celularity's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celularity's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celularity stock overvalued right now?
Based on GuruFocus' analysis, Celularity (CELU) is currently considered Possible Value Trap. The stock's GF Value™ is $2.28, compared to a current price of $0.75 — trading 67.1% below its estimated fair value. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Celularity's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Celularity (CELU), the current Moat Score is 3 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celularity (CELU) Overvalued in 2026?

Based on GuruFocus' analysis, Celularity stock appears to be undervalued. The current stock price of $0.75 is trading 67.1% below its estimated GF Value™ of $2.28. GuruFocus considers Celularity to be Possible Value Trap.

Key valuation signals for CELU:

  • Moat Score: 3
  • GF Value™: $2.28 vs. price of $0.75 (67.1% below fair value)
  • GF Score™: 31/100 with 5 warning signs
  • Industry Position: 50% above the Biotechnology median (#341 of 1394)

No single metric tells the full story. See the CELU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celularity Business Description

Address 170 Park Avenue, Florham Park, NJ, USA, 07932
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
31GF Score

Get the complete analysis for CELU

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.75
Price
$2.28
GF Value